Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.7% |
| 2 | Financials | 7.47% |
| 3 | Consumer Discretionary | 6.7% |
| 4 | Communication Services | 6.02% |
| 5 | Healthcare | 4.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1426
CALL
IonQ
IONQ
$18.2B
| $14.6M | ﹤0.01% |
325,100
+227,600
| +233% | +$12.8M |
|
1427
CALL
C.H. Robinson
CHRW
$17.5B
| $14.6M | ﹤0.01% |
+90,700
| New | +$13.4M |
|
1428
Century Communities
CCS
$2.04B
| $14.5M | ﹤0.01% |
244,783
+27,683
| +13% | +$1.68M |
|
1429
FirstCash
FCFS
$9.14B
| $14.4M | ﹤0.01% |
90,467
-4,534
| -5% | -$714K |
|
|
PRMB
1430
Primo Brands
PRMB
$8.97B
| $14.4M | ﹤0.01% |
881,797
+278,436
| +46% | +$5.15M |
|
1431
WisdomTree India Earnings Fund ETF
EPI
$2.04B
| $14.4M | ﹤0.01% |
310,687
+99,874
| +47% | +$4.57M |
|
1432
Glacier Bancorp
GBCI
$6.48B
| $14.4M | ﹤0.01% |
326,297
+46,309
| +17% | +$2.03M |
|
1433
CALL
Hilton Worldwide
HLT
$72.2B
| $14.4M | ﹤0.01% |
50,000
| – | – |
|
|
CFLT
1434
PUT
DELISTED
Confluent
CFLT
| $14.4M | ﹤0.01% |
474,900
+449,900
| +1,800% | +$11M |
|
1435
TD Synnex
SNX
$20.4B
| $14.3M | ﹤0.01% |
95,487
-7,527
| -7% | -$1.15M |
|
1436
CALL
Pentair
PNR
$10.7B
| $14.3M | ﹤0.01% |
+137,200
| New | +$14.7M |
|
|
MRSH
1437
CALL
Marsh
MRSH
$90B
| $14.3M | ﹤0.01% |
+77,000
| New | +$14.4M |
|
1438
InterDigital
IDCC
$8.88B
| $14.3M | ﹤0.01% |
44,819
-11,944
| -21% | -$4.22M |
|
1439
GATX Corp
GATX
$6.33B
| $14.3M | ﹤0.01% |
84,126
-4,433
| -5% | -$731K |
|
1440
VanEck Oil Services ETF
OIH
$1.95B
| $14.3M | ﹤0.01% |
50,062
+4,947
| +11% | +$1.39M |
|
|
UPB
1441
Upstream Bio Inc
UPB
$379M
| $14.2M | ﹤0.01% |
524,499
+439,184
| +515% | +$10.9M |
|
1442
Doximity
DOCS
$4.74B
| $14.2M | ﹤0.01% |
321,274
+60,333
| +23% | +$3.39M |
|
1443
Telephone and Data Systems
TDS
$4.04B
| $14.2M | ﹤0.01% |
346,611
-89,619
| -21% | -$3.49M |
|
1444
CALL
Under Armour
UAA
$2.3B
| $14.2M | ﹤0.01% |
2,850,000
+1,350,000
| +90% | +$6.25M |
|
1445
Travere Therapeutics
TVTX
$5.79B
| $14.1M | ﹤0.01% |
369,530
+20,528
| +6% | +$667K |
|
1446
RLX Technology
RLX
$2.44B
| $14.1M | ﹤0.01% |
6,049,750
-63,800
| -1% | -$153K |
|
1447
Rhythm Pharmaceuticals
RYTM
$7.98B
| $14.1M | ﹤0.01% |
131,436
-10,949
| -8% | -$1.16M |
|
1448
Axsome Therapeutics
AXSM
$11.2B
| $14M | ﹤0.01% |
76,853
+4,786
| +7% | +$668K |
|
1449
Unum
UNM
$14.7B
| $14M | ﹤0.01% |
180,122
-156,508
| -46% | -$12M |
|
1450
CALL
Global Payments
GPN
$25.1B
| $13.9M | ﹤0.01% |
180,000
-2,121,600
| -92% | -$171M |
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $49.1B in Q4 2025, closing 641 positions and reducing 1,715 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 20% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.